Skip to main content

Opera newsletter - Sync your stuff with the new Opera browsers

The Opera Wire
Opera newsletter - Sync your stuff with the new Opera browsers

Recently, we released a new version of Opera Mini for Android and Opera 29 for Android and computers, with tab syncing. A few of our engineers took time out of their busy schedules to read some of the feedback - some of it proved to be pretty amusing.

 

Also in this edition, read about how we celebrated 10 million friends on Facebook.

 

The Opera Newsletter team
New Opera Mini for Android: What’s in the box?
Hey, Android fans, it’s time to unwrap the gift: this week we launched the new Opera Mini 8 for Android.
Read more
Access the same tabs from your computer and your Android phone
Our Mobile and Desktop teams have never had such a good reason to cooperate.
Read more
10m Opera friends on FaceBook!
We feel really excited and a bit humble today, to be honest. It’s not every day that a company gets to celebrate 10 million friends liking their Facebook page.
Read more
WATCH: Opera developers reading your tweets

We know Opera is not perfect. That’s why we read all your comments and tweets carefully.
Read more
our products
About Opera
Opera products enable more than 350 million internet consumers to discover and connect with the content and services that matter most to them, no matter what device, network or location.
Contact us
http://forums.opera.com Gjerdrums vei 19
NO-0484 OSLO
NORWAY
Social media
© 2015 Opera Software ASA. All Rights Reserved

 
Unsubscribe   /    Send to a friend
 






This email was sent to dbtech.hp.alert@blogger.com
why did I get this?    unsubscribe from this list    update subscription preferences
Opera Software · Gjerdrums vei 19, Oslo, Norway · Oslo, Oslo 0484 · Norway

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More